The packet contains no diagnostic methods or diagnostic criteria, so diagnostic approaches are not described here.

The packet certifies no approved treatments, foundational therapies, orphan-drug records, or GeneReviews management content. Treatment approaches are therefore unknown in this packet and are not described here.

Prognosis is not certified in this packet. It contains no natural history or outcome information, and none is stated here.

ClinicalTrials.gov records in the packet are mostly broader sarcoma or solid-tumor studies, and the packet does not state whether they enroll children. NCT06898970, a phase 2 study titled "Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma" (sponsor Varun Monga), is listed as recruiting, 2026-01-09 to 2029-10-31. NCT06673628, a phase 2 study titled "Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients" (National Cancer Center, Japan), is listed as recruiting, 2024-12-01 to 2029-11-30. NCT06239272, a phase 1 study of non-rhabdomyosarcoma soft tissue sarcoma (St. Jude Children's Research Hospital), is listed as recruiting, 2024-03-27 to 2037-06-01. One listed record, NCT01042379, concerns breast cancer. Trial titles do not establish intervention effects.